Cisplatin, vincristine, methotrexate, peplomycin, etoposide (COMPE) therapy for disseminated germ cell testicular tumors

International Journal of Urology

Volumn 4, Issue 1, 1997, Pages 47-51

  Yoshimura, Koji ^a   Yamauchi, Tamio ^a   Maeda, Hiroshi ^a   Kawai, Tsuneo ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Combination chemotherapy; Germ cell tumor; Testis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; GRANISETRON; HYDROCORTISONE SODIUM SUCCINATE; METHOTREXATE; PEPLEOMYCIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEVER; GERM CELL TUMOR; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; MALE; NAUSEA; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; TESTIS TUMOR;

EID: 0030964140     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1997.tb00139.x     Document Type: Article

References (23)

1. Cheng E, Cvitkovic E, Wittes RE, Golbey RB. Germ cell tumors: VAB II in metastatic testicular cancer. Cancer 1978;42:2162-2168.
2. Einhorn LH, Donohue JP. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-298.
3. Bosl GJ, Gluckman R, Geller NL, Golbey RB, Whitmore WF, Herr H, Sogani P, Morse M, Martini N, Bains M, McCormack P. VAB-6: An effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 1986;4:1493-1499.
4. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985;3:326-335.
5. Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, McElwain TJ, Hendry WF. The treatment of metastatic germ-cell testicular tumors with bleomycin, etoposide and cis-platin (BEP). Br J Cancer 1983;47:613-619.
6. Newlands ES, Bagshawe KD, Begent RHJ, Rustin GJS, Crawford SM, Holden L. Current optimum management of anaplastic germ cell tumors of the testis and other sites. Br J Urol 1986;58:307-314.
7. Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986;4:528-536.
8. Garrow GC, Johnson DH. Treatment of "good risk" metastatic testicular cancer. Semin Oncol 1992; 19: 159-165.
9. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA. Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 1986;6:400-407.
10. World Health Organization. WHO handbook for reporting results of cancer treatment. No. 48. Geneva: WHO offset publication, 1979.
11. Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 1975;36:318-326.
12. Kuo SH, Luh KT. Monitoring tumor cell kinetics in patients receiving chemotherapy for small cell lung cancer. Acta Cytologica 1993;37:353-357.
13. Liebmann JE, Fisher J, Teague D, Cook JA. Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells. Oncol Res 1994;5:25-31.
14. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993;29A:1843-1848.
15. Tobey RA. Different drugs arrest cells at a number of distinct stages in G2. Nature 1975;254:245-247.
16. Yamachi T, Okada K, Yoshida O. "Non-cross-resistant" sequential combination chemotherapy consisting of cis-diamminedichloroplatinum (II) mainly, based on synchronization theory, for human bladder cancer xenografts in athymic nude mice. Acta Urol Jpn 1986;32:1781-1797.
17. Samson MK, Rivkin SE, Jones SE, Costanzi JJ, LoBuglio AF, Stephens RL, Gehan EA, Cummings GD. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer: a Southwest Oncology Group study. Cancer 1984;53:1029-1035.
18. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988;6:1031-1040.
19. Ueda T, Yamauchi T, Kawai T, Ohono Y, Kawakami S, Yonese J. Low dose COMPE: cisplatin, vincristine, methotrexate, peplomycin, etoposide chemotherapy for advanced testicular cancer. Jpn J Urol 1994;85:626-631.
20. Nishio K, Saijo N. Effect of cisplatin on cell cycle regulators. Jpn J Cancer Chemother 1994;21:289-294.
21. Lock RB, Rhodes LJ, Xuelan Z, Galperina OV. Mechanism associated with circumvention of G2 arrest and potentiation of etoposide cytotoxicity by purine analogues in human tumor cells. Proc Am Assoc Cancer Res 1993;34:285.
22. Shinomiya N, Shinomiya M, Wakiyama H, Katsura Y, Rokutanda M. Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. Exp Cell Res 1994;210:236-242.
23. Muir CS, Nectoux J. Epidemiology of cancer of the testis and penis. J NCI Monogr 1979;53:157-164.